HRP20192213T1 - Farmaceutski pripravak koji sadrži mirabegron - Google Patents
Farmaceutski pripravak koji sadrži mirabegron Download PDFInfo
- Publication number
- HRP20192213T1 HRP20192213T1 HRP20192213TT HRP20192213T HRP20192213T1 HR P20192213 T1 HRP20192213 T1 HR P20192213T1 HR P20192213T T HRP20192213T T HR P20192213TT HR P20192213 T HRP20192213 T HR P20192213T HR P20192213 T1 HRP20192213 T1 HR P20192213T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- thickener
- weight
- preparation according
- hydrophobic substance
- Prior art date
Links
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 title claims 3
- 229960001551 mirabegron Drugs 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- 239000002562 thickening agent Substances 0.000 claims 6
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
- 235000013539 calcium stearate Nutrition 0.000 claims 2
- 239000008116 calcium stearate Substances 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 claims 2
- 235000010493 xanthan gum Nutrition 0.000 claims 2
- 239000000230 xanthan gum Substances 0.000 claims 2
- 229920001285 xanthan gum Polymers 0.000 claims 2
- 229940082509 xanthan gum Drugs 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920002148 Gellan gum Polymers 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 229920000161 Locust bean gum Polymers 0.000 claims 1
- 206010027566 Micturition urgency Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 206010036018 Pollakiuria Diseases 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229940014259 gelatin Drugs 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 235000010492 gellan gum Nutrition 0.000 claims 1
- 239000000216 gellan gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 235000010420 locust bean gum Nutrition 0.000 claims 1
- 239000000711 locust bean gum Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 229960002900 methylcellulose Drugs 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229940068984 polyvinyl alcohol Drugs 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000022934 urinary frequency Diseases 0.000 claims 1
- 230000036318 urination frequency Effects 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Claims (9)
1. Farmaceutski pripravak koji sadrži kompleks mirabegrona ili njegove farmaceutski prihvatljive soli s natrijevim polistiren sulfonatom, zgušnjivačem i hidrofobnom supstancom, naznačen time što je hidrofobna tvar magnezijev stearat i / ili kalcijev stearat.
2. Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time što je sadržaj hidrofobne tvari 0,5% težine do 35% težine u odnosu na težinu zgušnjivača.
3. Farmaceutski pripravak prema zahtjevu 1 ili 2, naznačen time, što je zgušnjivač jedan član ili dva ili više članova odabranih iz skupine koja se sastoji od ksantanske gume, guar gume, gume rogača, gelanske gume, karboksimetil celuloze natrija, želatine, hidroksietil celuloze, hidroksipropil celuloze, karagenana, metilceluloze, natrijevog alginata, hipromeloze i polivinil alkohola.
4. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 3, naznačen time, što je zgušnjivač ksantanska guma.
5. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 4, naznačen time, što je sadržaj zgušnjivača 1% težine do 70% težine u odnosu na težinu farmaceutskog pripravka.
6. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time, što farmaceutski pripravak je farmaceutski pripravak spreman za suspenziju.
7. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 6, naznačen time, što farmaceutski pripravak je farmaceutski pripravak za oralnu primjenu.
8. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 7, naznačen time, što farmaceutski pripravak je farmaceutski pripravak za liječenje jednog člana ili dva ili više članova, izabranih iz skupine koja se sastoji urinarne hitnosti, urinarne učestalosti, urinarne inkontinencije i prekomjerne aktivnosti neuropatskog detruzora, koji su povezani s prekomjerno aktivnim mjehurom.
9. Uporaba hidrofobne tvari odabrane iz skupine koja se sastoji od magnezijevog stearata, kalcijevog stearata i njihove kombinacije, za sprečavanje stvaranja nerastopljenih kvržica u pripremi farmaceutskog pripravka koji sadrži kompleks mirabegrona ili njegove farmaceutski prihvatljive soli s natrijevim polistiren sulfonatom i zgušnjivačem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015073911A JP2018090490A (ja) | 2015-03-31 | 2015-03-31 | ミラベグロン含有医薬組成物 |
| EP16773147.0A EP3278801B1 (en) | 2015-03-31 | 2016-03-31 | Pharmaceutical composition containing mirabegron |
| PCT/JP2016/060745 WO2016159267A1 (ja) | 2015-03-31 | 2016-03-31 | ミラベグロン含有医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192213T1 true HRP20192213T1 (hr) | 2020-03-20 |
Family
ID=57005157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192213TT HRP20192213T1 (hr) | 2015-03-31 | 2019-12-10 | Farmaceutski pripravak koji sadrži mirabegron |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10058536B2 (hr) |
| EP (1) | EP3278801B1 (hr) |
| JP (1) | JP2018090490A (hr) |
| CY (1) | CY1122352T1 (hr) |
| DK (1) | DK3278801T3 (hr) |
| ES (1) | ES2760673T3 (hr) |
| HR (1) | HRP20192213T1 (hr) |
| HU (1) | HUE046729T2 (hr) |
| LT (1) | LT3278801T (hr) |
| PL (1) | PL3278801T3 (hr) |
| PT (1) | PT3278801T (hr) |
| RS (1) | RS59626B1 (hr) |
| SI (1) | SI3278801T1 (hr) |
| WO (1) | WO2016159267A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6713734B2 (ja) * | 2015-07-02 | 2020-06-24 | 三栄源エフ・エフ・アイ株式会社 | 粉体組成物のダマの形成を抑制する方法 |
| JPWO2019167978A1 (ja) * | 2018-02-28 | 2021-02-04 | 大日本住友製薬株式会社 | 溶出が制御された水性懸濁型医薬製剤 |
| JPWO2019167977A1 (ja) * | 2018-02-28 | 2021-02-04 | 大日本住友製薬株式会社 | 水性懸濁型医薬製剤 |
| KR102067261B1 (ko) * | 2018-03-13 | 2020-01-16 | 충북대학교 산학협력단 | 미라베그론을 유효 성분으로 포함하는 서방형의 약학 조성물 및 이의 제조방법 |
| WO2022006336A1 (en) * | 2020-07-01 | 2022-01-06 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
| US11311518B1 (en) * | 2021-06-29 | 2022-04-26 | Jubilant Pharma Holdings Inc. | Parenteral dosage form of β3 adrenoreceptor agonists |
| CN114617881A (zh) * | 2022-02-19 | 2022-06-14 | 苏州海景医药科技有限公司 | 一种米拉贝隆组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2985714B2 (ja) | 1995-03-20 | 1999-12-06 | 栗田工業株式会社 | 抗菌性組成物 |
| EP1028111B1 (en) | 1997-10-17 | 2004-05-12 | Yamanouchi Pharmaceutical Co. Ltd. | Amide derivatives or salts thereof |
| US6514492B1 (en) * | 1999-07-14 | 2003-02-04 | Schering-Plough Veterinary Corporation | Taste masking of oral quinolone liquid preparations using ion exchange resins |
| CA2379987A1 (en) | 1999-07-29 | 2001-02-08 | Roxane Laboratories, Inc. | Opioid sustained-released formulation |
| JP3795365B2 (ja) | 2001-09-28 | 2006-07-12 | 和光堂株式会社 | 服薬補助食品 |
| US7342117B2 (en) | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
| US7750029B2 (en) | 2002-11-07 | 2010-07-06 | Astellas Pharma Inc. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
| JP4211668B2 (ja) | 2004-04-21 | 2009-01-21 | キユーピー株式会社 | ゾル状又はゲル状食品調製用粉末組成物 |
| CN1879610A (zh) | 2006-04-03 | 2006-12-20 | 哈尔滨工业大学 | 口服多肽药物缓释微胶囊的制备方法 |
| JP3930897B1 (ja) | 2006-08-16 | 2007-06-13 | 太陽化学株式会社 | 粘度発現性を改良した増粘用組成物 |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| WO2013147134A1 (ja) | 2012-03-30 | 2013-10-03 | アステラス製薬株式会社 | ミラベグロン含有医薬組成物 |
-
2015
- 2015-03-31 JP JP2015073911A patent/JP2018090490A/ja active Pending
-
2016
- 2016-03-31 SI SI201630525T patent/SI3278801T1/sl unknown
- 2016-03-31 PT PT167731470T patent/PT3278801T/pt unknown
- 2016-03-31 WO PCT/JP2016/060745 patent/WO2016159267A1/ja active Application Filing
- 2016-03-31 HU HUE16773147A patent/HUE046729T2/hu unknown
- 2016-03-31 US US15/553,107 patent/US10058536B2/en active Active
- 2016-03-31 DK DK16773147.0T patent/DK3278801T3/da active
- 2016-03-31 LT LTEP16773147.0T patent/LT3278801T/lt unknown
- 2016-03-31 EP EP16773147.0A patent/EP3278801B1/en active Active
- 2016-03-31 PL PL16773147T patent/PL3278801T3/pl unknown
- 2016-03-31 ES ES16773147T patent/ES2760673T3/es active Active
- 2016-03-31 RS RS20191517A patent/RS59626B1/sr unknown
-
2019
- 2019-12-04 CY CY20191101276T patent/CY1122352T1/el unknown
- 2019-12-10 HR HRP20192213TT patent/HRP20192213T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS59626B1 (sr) | 2020-01-31 |
| ES2760673T3 (es) | 2020-05-14 |
| EP3278801B1 (en) | 2019-11-13 |
| WO2016159267A1 (ja) | 2016-10-06 |
| CY1122352T1 (el) | 2021-01-27 |
| PT3278801T (pt) | 2019-12-18 |
| US10058536B2 (en) | 2018-08-28 |
| EP3278801A1 (en) | 2018-02-07 |
| JP2018090490A (ja) | 2018-06-14 |
| EP3278801A4 (en) | 2018-11-14 |
| PL3278801T3 (pl) | 2020-03-31 |
| DK3278801T3 (da) | 2019-12-16 |
| SI3278801T1 (sl) | 2020-01-31 |
| LT3278801T (lt) | 2020-01-10 |
| HUE046729T2 (hu) | 2020-03-30 |
| US20180036288A1 (en) | 2018-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192213T1 (hr) | Farmaceutski pripravak koji sadrži mirabegron | |
| HRP20200555T1 (hr) | Novi oblik davanja racekadotrila | |
| HRP20171518T1 (hr) | Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja | |
| RS53363B (en) | ORAL PHARMACEUTICAL TABLETS FOR THE CONTROLLED MESALAZINE RELEASE AND THE PROCESS OF OBTAINING THEM | |
| CL2018001474A1 (es) | Mezcla seca que comprende sal de alginato; goma vegetal hidrocoloide de galactamanano; y almidon para la fabricacion de una composicion de alginato para envoltura de productos alimenticios que ademas comprende: poliol; humo liquido; y un agente amortiguador tal como glucono-delta-lactona, ácido acético, y carbonato de sodio (divisional de 408-2017). | |
| RU2015110824A (ru) | Фармацевтическая или нутрицевтическая композиция с замедленным высвобождением и стойкостью к воздействию этанола | |
| JP2018021007A5 (hr) | ||
| RU2012131158A (ru) | Фармацевтическая композиция с контролируемым высвобождением лекарственного средства | |
| NZ602075A (en) | Abuse-resistant formulations | |
| HRP20171092T1 (hr) | Stabilna tekuća formulacija amg 416 (velkalcetid) | |
| PH12019550088A1 (en) | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | |
| JP2016534142A5 (hr) | ||
| HRP20161340T1 (hr) | Formulacije darunavira | |
| PH12020550009A1 (en) | Pharmaceutical preparation and preparation method therefor | |
| IN2014DE03239A (hr) | ||
| HRP20200891T1 (hr) | Laktoferin za liječenje upalnih bolesti crijeva (ibd) povezanih s bakterijskim napadom | |
| RU2013139558A (ru) | Фармацевтическая композиция, содержащая лекарственное средство, имеющее слабую растворимость в воде | |
| TR201001417A1 (tr) | Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu | |
| AR091862A1 (es) | Composicion acuosa para preparar capsula dura, metodo para preparar la composicion acuosa, capsula dura preparada utilizando la composicion acuosa, y metodo para reciclar residuos de la capsula dura | |
| EA201992382A3 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
| JP2014169318A5 (hr) | ||
| EP2486914A3 (en) | Stable, non-corrosive formulations for pressurized metered dose inhalers | |
| RU2015141792A (ru) | Сухие фармацевтические композиции, включающие наночастицы активного агента, связанные с частицами носителя | |
| JP2017520619A5 (hr) | ||
| JP2015533174A5 (hr) |